US biotechnology leader Amgen will establish a new Science & Innovation Centre in Hyderabad’s Genome Valley, integrating experimental science with advanced data and digital technologies. Expected to be operational in 2027, the centre strengthens Hyderabad’s position as a global hub for high‑value life‑sciences research.
Hyderabad’s ascent as a global life‑sciences powerhouse has taken a decisive step forward with Amgen’s announcement of a new Science & Innovation Centre in Genome Valley. The move places Telangana firmly on the map of high‑value biomedical research and deep‑tech innovation, aligning the city with Amgen’s elite global R&D network of seven research laboratories.
According to official release by the company on 11th Aug, the centre, scheduled to become operational in 2027, will integrate experimental wet‑laboratory science with advanced data, AI and digital technologies, accelerating the discovery and development of next‑generation medicines. Amgen executives describe the facility as a critical expansion of the company’s global research footprint, enabling faster learning cycles and more precise translation of scientific insights into therapeutic breakthroughs.
A Strategic Investment in India
Amgen’s decision reflects a broader shift in global biopharma strategy: the integration of computational science with traditional laboratory research. As drug discovery becomes increasingly data‑driven — from molecular modelling to precision‑medicine analytics — companies are building hybrid research environments that combine biology, chemistry, AI and digital engineering.
Dr Jay Bradner, Amgen’s Executive Vice President of Research and Development, Artificial Intelligence and Data, emphasised that the Genome Valley centre will “expand the way we integrate experimental science with data and technology across our global research capabilities,” complementing the company’s strong US‑based R&D footprint.
This integration is expected to accelerate drug‑development timelines, improve predictive accuracy in early‑stage research and enhance the precision of clinical‑candidate selection — areas where AI‑driven approaches have already demonstrated significant value.
Why Genome Valley?
Genome Valley has evolved into India’s most advanced life‑sciences cluster, hosting more than 200 companies across pharmaceuticals, vaccines, biotechnology, contract research and manufacturing. Its infrastructure, talent pool and regulatory environment have made it a preferred destination for global R&D investments.
Telangana’s IT and Industries Minister, D. Sridhar Babu, noted that Hyderabad has “built one of the world’s strongest life sciences ecosystems, with deep capabilities in pharmaceuticals and vaccines,” and that Amgen’s investment marks the beginning of a new chapter focused on discovery‑led innovation.
The minister added that the centre reinforces Hyderabad’s role as a global hub for high‑value research, bringing together scientific talent, technology and industry at scale — a combination essential for developing the next generation of medicines and therapies.
Scientific Capabilities and Research Focus
The new centre will bring together scientists and technologists specialising in:
· Discovery chemistry
· Drug metabolism and pharmacokinetics (DMPK)
· Precision medicine
· Data science and digital technologies
These capabilities will be closely integrated with Amgen’s global research sites, enabling seamless collaboration across continents.
This model reflects a modern R&D philosophy: distributed expertise connected through shared digital platforms, unified data environments and collaborative scientific workflows.
By combining wet‑lab experimentation with computational modelling, the centre aims to:
· accelerate early‑stage drug discovery,
· improve prediction of drug behaviour in humans,
· enhance safety and efficacy modelling,
· support precision‑medicine approaches for complex diseases.
Such capabilities are particularly relevant to Amgen’s focus on oncology, inflammation, cardiometabolic disorders and rare diseases — areas where biological complexity demands sophisticated analytical tools.
Strengthening India’s Role in Global Biopharma
Amgen executives have highlighted India’s growing importance in the company’s global R&D network. Som Chattopadhyay, Senior Vice President of Global Business Solutions and National Executive at Amgen, stated that the new centre “reflects Amgen’s commitment to advancing scientific excellence, and India will be an important part of our global R&D network.”
Hyderabad’s STEM talent, strong academic institutions and established biopharma ecosystem provide a fertile environment for advanced research. The new centre will complement Amgen’s existing technology and innovation operations in the city, enabling closer integration between laboratory science and digital innovation.
The establishment of a global‑scale research centre by a Fortune 500 biopharma company is expected to generate significant economic and scientific benefits:
1. High‑skilled job creation
The centre will attract chemists, biologists, pharmacokinetic experts, data scientists, AI engineers and digital‑health specialists.
2. Strengthening the innovation ecosystem
Amgen’s presence is likely to catalyse collaborations with universities, startups, CROs and technology companies in Genome Valley.
3. Global visibility for Hyderabad
The investment reinforces Hyderabad’s reputation as a destination for cutting‑edge biomedical research, complementing its leadership in vaccines and pharmaceuticals.
4. Acceleration of translational research
The integration of computational and experimental science will support faster development of therapies with global impact. Amgen’s Science & Innovation Centre represents more than a corporate expansion — it is a strategic investment in India’s scientific future. As global biopharma increasingly relies on AI‑driven discovery, India’s combination of scientific talent and digital expertise positions it as a natural partner for next‑generation research.
For Hyderabad, the centre marks a shift from being a manufacturing and vaccine powerhouse to becoming a discovery‑driven innovation hub — a place where new medicines can be conceived, developed and prepared for global impact.
